Crowded psoriasis market cuts Lilly’s mirikizumab ambitionsEli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file Share XCrowded psoriasis market cuts Lilly’s mirikizumab ambitionshttps://pharmaphorum.com/news/crowded-psoriasis-market-cuts-lillys-mirikizumab-ambitions/
Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trialA phase 3 trial of Lilly’s inflammatory diseases challenger mirikizumab in ulcerative colitis has met its target – Share XLilly’s mirikuzumab hits target in phase 3 ulcerative colitis trialhttps://pharmaphorum.com/news/lillys-mirikuzumab-hits-target-in-phase-3-ulcerative-colitis-trial/
Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasisEli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, Share XLilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasishttps://pharmaphorum.com/news/lillys-mirikizumab-tops-novartis-blockbuster-cosentyx-in-psoriasis/
